Akari Therapeutics, Plc
AKTX
$0.34
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.75% | 39.07% | -8.17% | -97.75% | -116.37% |
| Total Depreciation and Amortization | -92.86% | -93.33% | -93.75% | 250.00% | 250.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,174.36% | -65.72% | 631.02% | 112.33% | 101.57% |
| Change in Net Operating Assets | -78.44% | -18.30% | 325.33% | 855.08% | 566.02% |
| Cash from Operations | 34.95% | 42.90% | 31.66% | 23.61% | 7.06% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 109.81% | -100.30% | -- | -- | 99,800.00% |
| Total Debt Repaid | -115.76% | -273.08% | -901.86% | -- | -- |
| Issuance of Common Stock | -26.73% | -26.73% | 132.41% | 70.25% | 23.86% |
| Repurchase of Common Stock | -- | -10,600.00% | -10,600.00% | -10,600.00% | -10,600.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -22.56% | -43.53% | 118.09% | 56.52% | 23.96% |
| Foreign Exchange rate Adjustments | 100.00% | 450.00% | -50.00% | -157.14% | -96.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.99% | 53.20% | 112.97% | 87.39% | 58.37% |